Mark Mirochnick
Overview
Explore the profile of Mark Mirochnick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1812
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Abrams E, Capparelli E, Ruel T, Mirochnick M
Clin Infect Dis
. 2022 Nov;
75(Suppl 4):S562-S570.
PMID: 36410381
Long-acting antiretroviral products have the potential to transform human immunodeficiency virus (HIV) prevention and treatment approaches in pediatric populations. Broadly neutralizing antibodies and/or long-acting antiretroviral formulations by injection could dramatically...
12.
Coutinho C, Warshaw M, Duarte G, Stek A, Violari A, Hofer C, et al.
J Acquir Immune Defic Syndr
. 2022 Sep;
91(4):403-409.
PMID: 36049477
Background: Integrase inhibitors have been associated with excess gestational weight gain that may lead to adverse pregnancy outcomes (APOs). This post hoc analysis of NICHD P1081 compared antepartum changes in...
13.
Liyanage M, Nikanjam M, McFadyen L, Vourvahis M, Rogg L, Moye J, et al.
Pediatr Infect Dis J
. 2022 Aug;
41(11):885-890.
PMID: 35980827
Background: Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing...
14.
Brooks K, Pinilla M, Stek A, Shapiro D, Barr E, Febo I, et al.
J Acquir Immune Defic Syndr
. 2022 Feb;
90(3):343-350.
PMID: 35195573
Background: Tenofovir alafenamide (TAF) is a key component of HIV treatment, but pharmacokinetic data supporting the use of TAF during pregnancy are limited. In this study, we report pharmacokinetic, safety,...
15.
Beranger A, Bekker A, P Solans B, Cotton M, Mirochnick M, Violari A, et al.
Clin Infect Dis
. 2022 Feb;
75(6):1037-1045.
PMID: 35134861
Background: Isoniazid (INH) metabolism depends on the N-acetyl transferase 2 (NAT2) enzyme, whose maturation process remains unknown in low birth weight (LBW) and preterm infants. We aimed to assess INH...
16.
Bekker A, Capparelli E, Violari A, Cotton M, Cababasay M, Wang J, et al.
Lancet HIV
. 2021 Dec;
9(1):e24-e31.
PMID: 34883066
Background: No evidence-based optimal dosing guidance is available for abacavir liquid formulation use from birth. We used abacavir pharmacokinetic data from neonates and infants to determine an exact abacavir dosing...
17.
Momper J, Wang J, Stek A, Shapiro D, Powis K, Paul M, et al.
J Acquir Immune Defic Syndr
. 2021 Nov;
89(3):303-309.
PMID: 34732682
Background: This study evaluated atazanavir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples. Setting: A nonrandomized, open-label, parallel-group, multicenter prospective study of atazanavir and cobicistat...
18.
Zhao S, Gockenbach M, Grimstein M, Sachs H, Mirochnick M, Struble K, et al.
Front Pediatr
. 2021 Nov;
9:721059.
PMID: 34722417
Alterations in plasma protein concentrations in pregnant and postpartum individuals can influence antiretroviral (ARV) pharmacokinetics. Physiologically-based pharmacokinetic (PBPK) models can serve to inform drug dosing decisions in understudied populations. However,...
19.
Denti P, Wasmann R, Francis J, McIlleron H, Sugandhi N, Cressey T, et al.
Lancet Child Adolesc Health
. 2021 Oct;
6(1):9-10.
PMID: 34678142
No abstract available.
20.
Piscitelli J, Nikanjam M, Best B, Acosta E, Mirochnick M, Clarke D, et al.
J Acquir Immune Defic Syndr
. 2021 Oct;
89(1):108-114.
PMID: 34629412
Background: A knowledge gap exists for dolutegravir (DTG) pharmacokinetics and safety during the first 4 weeks of life, preventing safe and effective DTG use in neonates. Setting: Population pharmacokinetic modeling...